NYSE:RITM
NYSE:RITMMortgage REITs

Assessing Rithm Capital’s valuation as expansion into third‑party asset management and spin‑off plans gain traction

Rithm Capital (RITM) is back in focus after a fresh wave of strategic moves, from buying Crestline and Sculptor to exploring a spin off of its origination and servicing operations. See our latest analysis for Rithm Capital. Despite the recent pullback in its 90 day share price return, Rithm’s steady year to date share price gain and strong multi year total shareholder returns suggest sentiment is still constructive as investors weigh these expansion moves and spin off optionality. If Rithm’s...
NasdaqGS:CGNX
NasdaqGS:CGNXElectronic

Has Cognex’s Long Slide and Recent Pullback Created an Opportunity in 2025?

Wondering if Cognex at around $36.88 is a bargain in disguise or a value trap in plain sight? This article walks through what the numbers are really saying about the stock. Despite being up 3.3% year to date, Cognex shares have slipped 5.2% over the last week and 4.0% over the last month, capping off a much rougher 3-year slide of 23.6% and a 52.3% drop over 5 years that has clearly reset expectations. Recent moves have come as investors reassess machine vision and factory automation names...
NYSE:PL
NYSE:PLProfessional Services

Planet Labs (PL) Q3 2026 EPS Worsening Challenges Bullish Profitability Narratives

Planet Labs PBC (PL) just posted another quarterly update with Q3 2026 revenue of about $81.3 million, basic EPS of roughly -$0.19, and trailing-12-month revenue sitting near $282.5 million alongside TTM EPS of around -$0.43. This keeps the profitability story clearly in the red even as the top line builds. The company has seen revenue move from about $61.3 million in Q3 2025 to $81.3 million in Q3 2026, while quarterly EPS has slid from roughly -$0.07 to -$0.19 over the same stretch,...
NYSE:CXM
NYSE:CXMSoftware

How Investors May Respond To Sprinklr (CXM) Q3 Beat And New 2026 Revenue Guidance

In early December 2025, Sprinklr reported third-quarter revenue of US$219.07 million and net income of US$2.9 million, alongside new fourth-quarter and full-year 2026 revenue guidance of US$216.5–217.5 million and US$853–854 million, respectively. Award recognition from ADWEEK and L’Oréal’s large-scale use of Sprinklr Advocacy, which generated very large organic impressions and a 4x return on investment, underline how major brands are using Sprinklr’s AI-native platform to run social media,...
NYSE:WFC
NYSE:WFCBanks

What Wells Fargo (WFC)'s AI Job Cuts, Digital Push, and Legal Settlement Mean For Shareholders

Wells Fargo recently reached a US$33.00 million global settlement over lawsuits alleging it facilitated deceptive subscription schemes, while also issuing several new senior unsecured notes maturing between 2029 and 2040 and outlining plans to cut headcount as artificial intelligence is rolled out across its operations. A Wells Fargo survey shows Gen Z and Millennials rapidly shifting toward digital cash gifts and tips via platforms like Zelle, underscoring how changing customer payment...
NYSE:ALLE
NYSE:ALLEBuilding

Is Allegion Share Price Still Attractive After 28% 2025 Rally and IoT Expansion?

If you are wondering whether Allegion at around $164 a share is still a smart buy or if the easy gains are behind it, this breakdown will help you decide whether the current price makes sense. The stock is up 2.4% over the last week and 28.1% year to date, even after a modest 1.7% dip over the past month. This suggests that the market still sees solid long term potential in the story. Recent headlines have focused on Allegion expanding its presence in electronic and IoT enabled security...
NasdaqGM:CRMD
NasdaqGM:CRMDPharmaceuticals

Does CorMedix’s (CRMD) Insider Sale After a Strong Quarter Clarify or Complicate Its Growth Story?

On 9 December 2025, CorMedix director Steven W. Lefkowitz sold 40,000 shares of common stock for about US$475,200, leaving him with 80,498 shares, shortly after the company reported Q3 2025 earnings and revenue that significantly exceeded market forecasts. The combination of robust quarterly results and insider selling draws attention to how CorMedix’s recent operational momentum aligns with leadership’s portfolio decisions. With CorMedix’s Q3 earnings beating expectations, we’ll examine how...
NasdaqGS:KDP
NasdaqGS:KDPBeverage

Keurig Dr Pepper (KDP): Assessing Valuation After Recent Share Price Momentum

Keurig Dr Pepper (KDP) has been quietly grinding higher, with the stock up about 10% over the past month and 8% in the past 3 months, even as its year to date return remains negative. See our latest analysis for Keurig Dr Pepper. That recent 30 day share price momentum of just over 10% is starting to chip away at a tougher year to date patch, even though the one year total shareholder return is still slightly negative. This suggests sentiment may be cautiously turning as investors reassess...
NasdaqGS:PRDO
NasdaqGS:PRDOConsumer Services

Assessing Perdoceo Education (PRDO)’s Valuation After a Recent Share Price Pullback

Perdoceo Education (PRDO) has quietly pulled back almost 9% over the past month even as its longer term track record and steady revenue and earnings growth paint a very different picture for patient investors. See our latest analysis for Perdoceo Education. The recent slide looks more like a breather than a breakdown, with a 30 day share price return of negative 8.9% coming after a solid year to date share price gain and a standout three year total shareholder return above 120%. This suggests...
NasdaqGS:ASYS
NasdaqGS:ASYSSemiconductor

Amtech Systems (ASYS) Q4 Profit of $0.07 EPS Tests Bearish Margin Narratives

Amtech Systems (ASYS) has just posted its FY 2025 fourth quarter numbers, with revenue of about $19.8 million and EPS of roughly $0.07 setting the tone for the latest print. Over the past six quarters, the company has seen quarterly revenue move from about $24.1 million in Q4 2024 to a peak of $26.7 million in Q3 2024 before landing at $19.8 million in Q4 2025. Over the same period, EPS has swung from a loss of roughly $0.04 in Q4 2024 to a deep trough of about negative $2.23 in Q2 2025 and...
NasdaqGS:BIIB
NasdaqGS:BIIBBiotechs

Biogen (BIIB) Is Down 5.2% After HSBC Downgrade Amid Mixed Drug Pipeline Signals – Has The Bull Case Changed?

In recent days, Stoke Therapeutics and Biogen reported encouraging long-term Phase 1/2a and extension data for zorevunersen in Dravet syndrome, while Eisai and Biogen shared new clinical and real-world insights on LEQEMBI and its subcutaneous formulation for early Alzheimer’s disease, alongside additional regulatory milestones and broader market access moves. Yet, HSBC’s downgrade of Biogen on concerns over declining CD20 collaboration royalties and growth risks highlights how questions...
NasdaqCM:RCT
NasdaqCM:RCTRetail Distributors

RedCloud Holdings (RCT) Revenue Surge Tests Bullish Growth Narrative Despite Deepening Losses

RedCloud Holdings (NasdaqCM:RCT) just posted its H1 2025 scorecard, with trailing twelve month revenue of about $48.4 million and a basic EPS of roughly -$1.76. This sets a clear backdrop of rapid top line expansion paired with ongoing losses. The company has seen revenue move from $13.6 million in H2 2023 to $16.1 million in H1 2024 and then $30.4 million in H2 2024. Over those same halves, EPS shifted from about -$4.20 to -$0.51 and then a much steeper -$17.85. That combination of fast...
NYSE:MTN
NYSE:MTNHospitality

Vail Resorts (MTN) Q1 2026: Wider EPS Loss Tests Bullish Margin‑Improvement Narrative

Vail Resorts (MTN) opened fiscal Q1 2026 with revenue of about $271 million, a basic EPS loss of roughly $5.20, and net income excluding extra items of around negative $187 million, setting a cautious tone for the new season. The company has seen quarterly revenue move from about $260 million in Q1 2025 to roughly $271 million in Q1 2026, while basic EPS shifted from a loss of about $4.62 to a loss of roughly $5.20 over the same period, giving investors a mixed read on top line stability...
NasdaqGS:BELF.A
NasdaqGS:BELF.AElectronic

Bel Fuse (BELF.A): Assessing Valuation After a Strong Multi‑Month Share Price Rally

Bel Fuse (BELF.A) has quietly put up a strong run lately, with the stock gaining about 22% over the past month and more than 31% in the past 3 months. See our latest analysis for Bel Fuse. Zooming out, the recent rally fits into a much bigger move, with a strong year to date share price return helping push Bel Fuse to around $155.40 as investors warm to its growth trajectory and reassess risk. If Bel Fuse’s momentum has you rethinking your tech exposure, it might be a good moment to scan...
NasdaqGS:SKYW
NasdaqGS:SKYWAirlines

Does SkyWest Still Offer Value After Its 495% Three Year Surge?

If you have been wondering whether SkyWest at around $107 a share is still good value after its big comeback, you are not alone. This article is designed to walk you through that question step by step. The stock has climbed 5.2% over the last week, 10.6% over the past month, and 495.2% over three years, which naturally raises the question of how much upside, or downside, might be left from here. Recently, investors have been focused on SkyWest’s progress in rebuilding regional capacity and...
NYSE:MANU
NYSE:MANUEntertainment

Manchester United (NYSE:MANU) Q1 Loss Deepens, Testing Turnaround Profitability Narrative

Manchester United (NYSE:MANU) opened Q1 2026 with revenue of about £140.3 million and a basic EPS of roughly -£0.04, alongside net income of around -£6.6 million, keeping the club in loss-making territory even as it reports another busy quarter of activity. The club has seen quarterly revenue move between roughly £143.1 million and £198.7 million over the past year while EPS has swung from £0.01 to as low as about -£0.16, which sets up a narrative where a growing top line and negative EPS...
NYSE:BE
NYSE:BEElectrical

Has Bloom Energy’s 366% Surge Left Any Upside in 2025?

Wondering if Bloom Energy is still worth buying after its massive run up, or if the easy money has already been made? Let us break down what the recent action really implies for its underlying value. Despite a sharp pullback over the last week and month, with returns of -7.7% over 7 days and -14.2% over 30 days, the stock is still up an eye catching 366.4% year to date and 339.3% over the past year, with multi year gains above 300%. These swings have come as investor attention has shifted...
NasdaqGM:PAYO
NasdaqGM:PAYODiversified Financial

Should Payoneer’s AI Fraud Upgrade With Oscilar Require Action From Payoneer Global (PAYO) Investors?

Payoneer recently announced a partnership with Oscilar, integrating its AI- and machine-learning-based fraud and risk intelligence platform across Payoneer’s core global payment systems to improve predictive monitoring and automation. This upgrade in fraud prevention aims to tighten risk controls while keeping customer interactions smooth, which could strengthen Payoneer’s competitive position in cross-border payments for small and medium-sized businesses. Next, we’ll examine how Payoneer’s...
NYSE:AMTM
NYSE:AMTMProfessional Services

Assessing Amentum (AMTM) Valuation After Major CTRIC IV and DISA Contract Wins

Amentum Holdings (AMTM) just added another long term growth lever, landing a prime spot on the Defense Threat Reduction Agency's $3.5 billion CTRIC IV program alongside a fresh $120 million DISA computing services win. See our latest analysis for Amentum Holdings. Those twin defense wins seem to be feeding into the story, with the latest share price at $30.13 and a punchy 1 month share price return of 31.23% capping a 39.10% year to date share price gain. This suggests momentum is building as...
NasdaqGS:SVRA
NasdaqGS:SVRABiotechs

Savara (SVRA) Is Up 8.9% After European Patent Boost For MOLBREEVI Nebulized Therapy

Savara Inc. recently announced that the European Patent Office intends to grant a patent covering the liquid formulation of MOLBREEVI, its orally inhaled GM-CSF therapy delivered via the eFlow Nebulizer System for the rare lung disease autoimmune pulmonary alveolar proteinosis. This prospective patent, alongside multiple expedited and orphan designations in the U.S., EU and U.K., could materially extend MOLBREEVI’s protection and enhance the company’s respiratory disease franchise if...
NYSE:CB
NYSE:CBInsurance

SuretyBind Digital Platform Initiative Could Be A Game Changer For Chubb (CB)

Earlier this week, Chubb, The Hartford, Liberty Mutual and Travelers jointly formed SuretyBind, LLC, a technology company creating a shared digital infrastructure to modernize the surety market’s data transmission and digital bond execution. This collaboration highlights how leading surety providers are pooling technology resources to streamline bond workflows, enhance verification, and reduce fraud risk across the entire ecosystem. We’ll now explore how Chubb’s role in building this shared...
NasdaqGS:SNPS
NasdaqGS:SNPSSoftware

Synopsys (SNPS) Margin Compression to 18.1% Tests Bullish High-Growth Valuation Narrative

Synopsys (SNPS) just wrapped up FY 2025 with fourth quarter revenue of about $2.3 billion and basic EPS of $2.42, capping a year in which trailing 12 month revenue reached roughly $7.1 billion and EPS came in at $8.15. The company has seen quarterly revenue move from about $1.6 billion in the fourth quarter of FY 2024 to $2.3 billion in the latest quarter, while basic EPS shifted from $1.81 to $2.42 over the same period. This sets up a story in which investors will be weighing headline growth...
NasdaqCM:RCAT
NasdaqCM:RCATElectronic

Red Cat (RCAT) Leadership Reshuffle: How the New C‑Suite Shapes the Drone Maker’s Valuation Narrative

Red Cat Holdings (RCAT) just shuffled its C suite, promoting former CFO Christian Ericson to COO and bringing in finance veteran Christian Morrison as the new CFO, a move squarely aimed at execution. See our latest analysis for Red Cat Holdings. The leadership reshuffle comes as investors reassess Red Cat’s trajectory, with the stock’s latest share price at $8.79, a weak 90 day share price return of negative 20.02 percent, but a striking three year total shareholder return of 691.89 percent,...
NYSE:RPM
NYSE:RPMChemicals

Does RBC’s Infrastructure-Focused Upgrade Reframe the Bull Case for RPM International (RPM)?

Earlier this week, RBC Capital Markets upgraded RPM International to Outperform, highlighting the company’s expanding infrastructure-focused specialty chemicals portfolio, ongoing efficiency initiatives, and a 5.9% dividend increase that extends its multi-decade streak of annual raises. The combination of a more infrastructure-weighted business mix, sustained free cash flow generation, and continued dividend growth is reshaping how investors assess RPM’s balance between income, growth, and...